Drug updated on 10/18/2024
| Dosage Form | Tablet (oral; 12.5 mg) |
| Drug Class | Endothelin receptor antagonists |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other drugs
- Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions.
Latest News
Summary
- This summary is based on the review of one systematic review(s)/meta-analysis(es). [1]
- Aprocitentan (Tryvio) and other novel drugs, including non-steroid mineralocorticoid receptor antagonists and selective aldosterone synthase inhibitors, have shown effectiveness in lowering seated office and 24-hour ambulatory systolic/diastolic blood pressure in patients with resistant hypertension (RHT) when added to a regimen of 2-3 antihypertensive drugs.
- The effectiveness of these drugs, including aprocitentan as a dual endothelin receptor antagonist, has been demonstrated in phase 2 RCTs for RHT patients, but the review does not specify comparative effectiveness between aprocitentan and other novel drug classes.
- No differences in effectiveness across population subgroups or types were detailed in the review for the RHT patient population.
- There is no safety information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Tryvio (aprocitentan) Prescribing Information. | 2024 | Idorsia Pharmaceuticals US Inc., Radnor, PA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Systematic Review Article: New Drug Strategies for Treating Resistant Hypertension-the Importance of a Mechanistic, Personalized Approach | 2024 | High Blood Pressure & Cardiovascular Prevention |